Literature DB >> 11082096

Sentinel node biopsy for malignant melanoma. Having this biopsy gives psychological benefits.

S S Rayatt, S Hettiaratchy, A Key, B W Powell.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 11082096      PMCID： PMC1119018     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

1.  Histopathological workup of sentinel lymph nodes: how much is enough?

Authors:  P J van Diest
Journal:  J Clin Pathol       Date:  1999-12       Impact factor: 3.411

2.  The argument against sentinel node biopsy for malignant melanoma.

Authors:  J M Thomas; E J Patocskai
Journal:  BMJ       Date:  2000-07-01

Review 3.  The role of clinical trials in assessing optimal treatment of cutaneous melanoma not extending beyond the regional nodes.

Authors:  N Cascinelli
Journal:  Eur J Surg Oncol       Date:  1996-04       Impact factor: 4.424

4.  A new American Joint Committee on Cancer staging system for cutaneous melanoma.

Authors:  C M Balch; A C Buzaid; M B Atkins; N Cascinelli; D G Coit; I D Fleming; A Houghton; J M Kirkwood; M F Mihm; D L Morton; D Reintgen; M I Ross; A Sober; S J Soong; J A Thompson; J F Thompson; J E Gershenwald; K M McMasters
Journal:  Cancer       Date:  2000-03-15       Impact factor: 6.860

5.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

Authors:  J M Kirkwood; J G Ibrahim; V K Sondak; J Richards; L E Flaherty; M S Ernstoff; T J Smith; U Rao; M Steele; R H Blum
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

6.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.

Authors:  D L Morton; J F Thompson; R Essner; R Elashoff; S L Stern; O E Nieweg; D F Roses; C P Karakousis; N Mozzillo; D Reintgen; H J Wang; E C Glass; A J Cochran
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

7.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.

Authors:  C M Balch; S J Soong; A A Bartolucci; M M Urist; C P Karakousis; T J Smith; W J Temple; M I Ross; W R Jewell; M C Mihm; R L Barnhill; H J Wanebo
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

8.  Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma.

Authors:  J Norman; C W Cruse; C Espinosa; C Cox; C Berman; R Clark; H Saba; K Wells; D Reintgen
Journal:  Am J Surg       Date:  1991-11       Impact factor: 2.565

9.  Follow-up in stage I cutaneous malignant melanoma: an audit.

Authors:  C A Baughan; V L Hall; B J Leppard; P J Perkins
Journal:  Clin Oncol (R Coll Radiol)       Date:  1993       Impact factor: 4.126

10.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Authors:  J M Kirkwood; M H Strawderman; M S Ernstoff; T J Smith; E C Borden; R H Blum
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544
View more
  2 in total

Review 1.  Malignant melanoma (non-metastatic): sentinel lymph node biopsy.

Authors:  Andy Pay
Journal:  BMJ Clin Evid       Date:  2016-01-19

2.  [Sentinel lymph node excision (SLNE) and positron emission tomography in the staging of stage I-II melanoma patients].

Authors:  A Schäfer; R A Herbst; U Beiteke; S Lange-Ionescu; H Treckmann; D Löhlein; G Thiemann; B Theophil; E-W Schwarze; H-J Bartels; P J Frosch
Journal:  Hautarzt       Date:  2003-01-15       Impact factor: 0.751
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.